EP Patent

EP1905439A1 — Second line treatment of metastatic hormone refractory prostate cancer using satraplatin

Assigned to Agennix AG · Expires 2008-04-02 · 18y expired

What this patent protects

The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2 nd line treatment of metastatic hormone refractory prostate cancer.

USPTO Abstract

The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2 nd line treatment of metastatic hormone refractory prostate cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP1905439A1
Jurisdiction
EP
Classification
—
Expires
2008-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Agennix AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.